Pertuzumab biosimilar - Mabscale
Latest Information Update: 29 Aug 2023
At a glance
- Originator Mabscale
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Breast cancer
Most Recent Events
- 20 Jul 2023 Phase-I clinical trials in Breast cancer (In volunteers) in Russia (IV) (NCT05825781)
- 02 May 2023 Mabscale plans a phase I pharmacokinetic trial (In volunteers) in Russia (IV) (NCT05825781)
- 02 May 2023 Preclinical trials in Breast cancer in Russia (IV) (NCT05825781)